Loading
Life sciences · Journal article
Radiation Oncology · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
To evaluate long-term oncologic outcomes and toxicity of moderate hypofractionated proton beam therapy (PBT) in patients with localized prostate cancer. We retrospectively analyzed 192 patients with localized prostate cancer (cT1–T4N0M0) treated with definitive PBT between 2010 and 2021. All patients received 70 Gy (RBE) in 28 fractions. Androgen deprivation therapy (ADT) was administered in 26.6% of patients. The primary endpoint was biochemical failure-free survival (BFFS), defined by the Phoenix criteria. Secondary endpoints included local progression-free survival (LPFS), prostate cancer-specific survival (PCSS), and treatment-related toxicity. Survival outcomes were estimated using the Kaplan–Meier method. With a median follow-up of 90.6 months, the 10-year BFFS rate was 78.5%. Risk-stratified 10-year BFFS rates were 100.0%, 80.3%, and 66.6% for low-, intermediate-, and high-risk groups, respectively. The overall 10-year LPFS rate was 91.3% (100.0%, 88.9%, and 89.0% for low-, intermediate-, and high-risk groups, respectively), and the 10-year PCSS rate was 100.0% in all risk groups. Among 27 patients with biochemical recurrence, intraprostatic local recurrence ( n = 11) was the most common clinical failure pattern. On multivariable analysis, NCCN risk group and ADT use were significantly associated with BFFS. Grade ≥ 3 gastrointestinal and genitourinary toxicities were uncommon, occurring in 5.2% and 3.1% of patients, respectively, with no treatment-related deaths. Moderate hypofractionated PBT provides favorable long-term disease control with acceptable toxicity in localized prostate cancer, despite a relatively high proportion of high-risk patients and limited ADT use. Intraprostatic recurrence appeared to be the predominant pattern of clinical failure in this cohort. Not applicable.